Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Citalopram (Primary) ; Reboxetine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 22 Mar 2012 Actual initiation date changed from 1 Nov 2008 to 27 Jul 2008 as reported by European Clinical Trials Database.
- 02 Mar 2011 New trial record